Official websites use .gov
Secure .gov websites use HTTPS
Novel anticoagulants achieve rapid market penetration despite higher costs
Novel anticoagulants achieve rapid market penetration despite higher costs
- Collection:
- Health Policy and Services Research
- Series Title(s):
- Spotlight (AARP Public Policy Institute)
- Author(s):
- Gillespie, Catherine W., author
Purvis, Leigh, author - Contributor(s):
- AARP (Organization), issuing body.
Public Policy Institute (AARP (Organization)), issuing body. - Publication:
- Washington, DC : AARP Public Policy Institute, June 2021
- Language(s):
- English
- Format:
- Text
- Subject(s):
- Anticoagulants -- economics
Anticoagulants -- therapeutic use
Administration, Oral
Diffusion of Innovation
United States - Genre(s):
- Technical Report
- Abstract:
- Stroke is a leading cause of disability in the United States--and the fifth leading cause of death. Patients with atrial fibrillation are five times more likely to suffer a stroke and may be prescribed anticoagulants to reduce this elevated risk. These medications prevent blood clots from forming when irregular heart rhythms caused by atrial fibrillation allow blood to pool in the heart. Warfarin, an oral anticoagulant that was originally approved in 1954 and is widely available in generic form, was previously the standard treatment for stroke prevention in patients with atrial fibrillation. Warfarin requires frequent monitoring and dose adjustments to address risks of uncontrolled bleeding events; it also carries multiple drug and diet interactions that may increase risk of side effects or decrease therapeutic effectiveness for some users. In October 2010, novel oral anticoagulants (NOACs) began entering the market as an alternative to warfarin for patients with nonvalvular atrial fibrillation. NOACs have a different mechanism of action and do not require frequent monitoring or dose adjustments. Notably, the products were also priced substantially higher than existing therapies. Given this changing landscape, we sought to assess trends in use of, and spending on, oral anticoagulants--both warfarin and NOACs.
- Copyright:
- Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY-NC-ND license. (More information)
- Extent:
- 1 online resource (1 PDF file (7 pages))
- Illustrations:
- Illustrations
- NLM Unique ID:
- 9918317782806676 (See catalog record)
- Permanent Link:
- http://resource.nlm.nih.gov/9918317782806676